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Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma have a better overall survival
than those with residual disease. Many classification systems assessing pathological response to neoadjuvant chemotherapy include
residual ductal carcinoma in situ (DCIS) only in the definition of pathological complete response. The purpose of this study was to
investigate whether patients with residual DCIS only have the same prognosis as those with no residual invasive or in situ disease. A
retrospective analysis of a prospectively maintained database identified 435 patients, who received neoadjuvant chemotherapy for
operable breast cancer between February 1985 and February 2003. Of these, 30 (7%; 95% CI 5–9%) had no residual invasive disease
or DCIS and 20 (5%; CI 3–7%) had residual DCIS only. With a median follow-up of 61 months, there was no statistical difference in
disease-free survival, 80% (95% CI 60–90%) in those with no residual invasive or in situ disease and 61% (95% CI 35–80%) in those
with DCIS only (P¼0.4). No significant difference in 5-year overall survival was observed, 93% (95% CI 75–98%) in those with no
residual invasive or in situ disease and 82% (95% CI 52–94%) in those with DCIS only (P¼0.3). Due to the small number of patients
and limited number of events in each group, it is not possible to draw definitive conclusions from this study. Further analyses of other
databases are required to confirm our finding of no difference in disease-free and overall survival between patients with residual DCIS
and those with no invasive or in situ disease following neoadjuvant chemotherapy for breast cancer.
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Neoadjuvant chemotherapy is now widely used in the treatment of
locally advanced or potentially operable large breast cancers.
Randomised trials have demonstrated neoadjuvant chemotherapy
reduces the need for mastectomy (Powles et al, 1995; Fisher et al,
1998), with similar overall survival rates to adjuvant chemotherapy
(Fisher et al, 1998). Women achieving no residual histological
evidence of tumour after chemotherapy at the time of surgery (i.e.
a pathological complete response (pCR)) have a significantly
improved survival (Bonadonna et al, 1998; Fisher et al, 1998;
Kuerer et al, 1999), and pCR is often used as an early surrogate
marker of treatment efficacy. However, there is no standard
method for grading pathological response of breast tumours to
neoadjuvant chemotherapy and a number of different classifica-
tion systems have been proposed (Chevallier et al, 1993; Sataloff
et al, 1995; Fisher et al, 1997; Honkoop et al, 1998; Kuerer et al,
1998; Ogston et al, 2003). Most, but not all, of these grading
schemes have included both no residual disease of any sort and
residual ductal carcinoma in situ (DCIS) without invasive disease
in the definition of pCR. We are unaware of published
confirmatory data to justify this, and we have therefore reviewed
the prognostic significance of residual DCIS alone following
neoadjuvant chemotherapy compared with no histological evi-
dence of any residual disease from our database. However, the
number achieving residual DCIS only and no invasive or in situ
disease is relatively small. For instance in NSABP B18, the largest
randomised trial, 88 out 682 patients (13%) were classified as
having no residual invasive disease following neoadjuvant
chemotherapy (Wolmark et al, 2001). Similarly, in another large
group of patients, treated within two prospective randomised
trials, 43 of 372 patients (12%) were recorded as achieving a pCR
(Kuerer et al, 1999). Thus, with a relatively small proportion of
patients achieving a pCR following neoadjuvant chemotherapy,
any comparison between those with residual DCIS and no invasive
or in situ disease will inevitably involve small numbers of patients.
PATIENTS AND METHODS
Patient characteristics
A sequential and prospectively maintained database at the Royal
Marsden Hospital, London, was retrospectively searched for
women who had received neoadjuvant chemotherapy for primary
operable breast cancer. Eligible patients had histologically
confirmed invasive breast cancer on core biopsy prior to
commencing chemotherapy and subsequently underwent surgery.
Patients who received neoadjuvant therapy between 1985 and
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sFebruary 2003 were included in the study and data available until
31st March 2005 were used in the analysis. The presence of
metastatic disease at diagnosis was excluded by chest radiograph,
full blood count and standard serum biochemistry. Further
investigations were performed if clinically indicated. Patients with
locally advanced disease (defined as inoperable by the Haagensen
criteria) or inflammatory breast cancer were excluded from this
analysis (Haagensen and Stout, 1943).
Pathological analysis
Although all patients were managed in the same institution,
and hence followed departmental protocols, due to the time
period, there was inevitably some difference in pathological
assessment over time. The number of blocks examined to record
residual disease varied with size of excision. Since the presence or
absence of disease will vary depending on the amount of tissue
examined, we looked at the mean and range of blocks taken in the
group with no residual disease vs the group with residual in situ
carcinoma only. The pathological data described in the study were
assessed on the initial core biopsy. This has clear limitations,
especially in assessing grade since mitotic counts over 10 high
powered fields is not always possible on such small samples.
Similarly, the oestrogen receptor (ER) staining can in rare cases be
sufficiently heterogeneous to give misleading results in small core
biopsy samples but in our experience, such profound hetero-
geneity leading to a change in status from positive to negative or
vice versa is uncommon. We have included this data with the
acknowledgement of this limitation. Involved surgical margins
contained tumour at the margin or tumour transected at the
margin. Close margins were defined as tumour within 1mm of the
margin.
Treatment
Neoadjuvant chemotherapy regimens included: (1) anthracycline-
based schedules comprising of doxorubicin 60mgm
 2 or epir-
ubicin 60mgm
 2 once every 3 weeks, often within the context of
clinical trials; (2) CMF (cyclophosphamide 100mg orally days
1–14, methotrexate 30mgm
 2 days 1 and 8, and 5-fluorouracil
1gm
 2 days 1 and 8); and occasionally (3) mitoxantrone-
containing regimens (up to 11mgm
 2). Treatment was usually
given to a total of six courses, and occasionally to eight in specific
trials.
Following each cycle of chemotherapy response was evaluated
clinically by measurement of the two largest diameters of the
tumour and graded according to the World Health Organisation
(WHO) response criteria (Miller et al, 1981).
Breast conserving surgery or mastectomy was performed
following chemotherapy. Conservative surgery involved macro-
scopic excision of the residual primary tumour with a surrounding
margin of normal tissue. Patients with residual invasive carcinoma
and microscopically involved radial margins (i.e. superior,
inferior, medial or lateral) were offered either a mastectomy or
wider excision. All patients who were treated with conservative
surgery received adjuvant radiotherapy. The dose range of
radiotherapy was 46–50Gy, with boosts to the tumour bed
ranging from 11.1 to 17.5Gy. If the axilla was not surgically
treated then radiotherapy was given to this region, with doses
ranging from 46 to 50Gy. If the axillary lymph nodes were
involved then radiotherapy to the supraclavicular fossa was given,
again dose ranging from 46 to 50Gy. Radiotherapy was also given
to patients with involved axillary lymph nodes after mastectomy.
Adjuvant tamoxifen, 20mgday
 1, was administered to all patients,
unless contraindicated. From 1997 onwards, patients who were ER
and progesterone receptor (PgR) negative were not treated with
tamoxifen.
Follow-up
Clinical response was assessed after each cycle of chemotherapy.
Following surgery, patients were reviewed every 3 months for
2 years and then 6 monthly until 5 years. Subsequently, yearly
clinical and mammographic examinations were performed.
Median follow-up was 5 years and 1 month.
Statistical methods
Disease-free and overall survival were measured from the start of
chemotherapy until relapse (death) or last follow-up. Survival
curves were calculated by the method of Kaplan and Meier (1958)
and differences were assessed by means of the log-rank statistic
(Peto et al, 1977). Local recurrence free survival was measured
from the start of chemotherapy until an isolated local recurrence
and the data were censored in the event of a distant metastasis.
RESULTS
Four hundred and thirty nine sequential patients treated with
neoadjuvant treatment for operable breast cancer at the Royal
Marsden Hospital between 1985 and February 2003 were
considered for this analysis. Four were excluded because pathology
was not available for review. Of the remaining 435 patients
included in the review, 22% had a clinical complete response with
a further 56% having a partial response (overall response rate
78%). At surgery 50 patients (11%) had either no residual disease
of any sort (30; 7%, 95% CI 5–9%) or had residual ductal
carcinoma in situ only (20; 5%, 95% CI 3–7%). The clinical and
pathological characteristics of those with no residual invasive or
in situ disease, residual DCIS and residual invasive carcinoma
are given in Table 1. There were three patients in both the pCR
and residual DCIS group who did not receive tamoxifen. The
chemotherapy schedules administered are displayed in Table 2.
There were 385 (89%) patients with residual invasive carci-
noma following neoadjuvant chemotherapy. Of these 385 patients,
90 had either minimal response, stable or progressive disease
on clinical assessment following neoadjuvant treatment. Of those
with residual carcinoma, 155 were treated with mastectomy and
230 with breast conserving surgery. This compared with 4
and 26 treated with mastectomy and breast conserving surgery
Table 1 Patient characteristics
Patient characteristic pCR Residual DCIS Residual invasive
Age (years)
Median (range) 48 (31–62) 43 (26–54) 48 (24–67)
Menopausal status
Pre 17 17 220
Peri 4 0 35
Post 7 2 100
Hysterectomy 2 1 30
ER status
Positive 11 10 250
Negative 16 7 88
Not known 3 3 47
Chemotherapy
Anthracycline 29 19 311
Nonanthracycline 1 1 74
Surgery
Conservative 26 12 230
Mastectomy 4 8 155
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srespectively in the pCR group. Of all patients treated with
mastectomy 102 patients received radiotherapy. For the residual
DCIS group, eight were treated with mastectomy and 12 with
breast conserving surgery. In the residual invasive carcinoma
group, 41 patients underwent re-excision due to involved radial
margins; 14 wider excision and 27 mastectomy. One patient in the
residual DCIS group had a wider excision due to DCIS involving a
radial margin. Of the 268 women treated with breast conservation
as final surgery, invasive carcinoma involved a radial margin in 18
(7%) cases and was recorded as close in 11 (4%) patients. In 4 (2%)
of the 268 patients DCIS involved a radial margin and in 18 (7%)
the margin status was unknown.
For the group of patients with residual in situ disease, the
mean number of slides was 18.8 (range 5–63). For the 30 patients
in whom there was a complete response with no residual invasive
or in situ disease, the mean number of slides examined was 17.4
(range 1–45). None of the patients had pathological axillary lymph
node involvement. The extent of residual DCIS ranged from 1 to
80mm, with four cases measuring over 50mm. For seven patients,
the exact measurement of residual DCIS was not available, and it
was not possible to retrospectively ascertain the exact size.
The 5-year disease-free survival in the pCR group was 80%
(95% CI 60–90%) and in those with residual DCIS 61% (95% CI
35–80%) (P¼0.4), see Figure 1. This compares with a 5-year
disease-free survival of 60% (95% CI 55–65%) in those with
residual invasive carcinoma. No significant difference in disease-
free survival was observed between those classified as pathological
complete responders (residual DCIS and no invasive or in situ
disease) compared to those with residual invasive carcinoma,
P¼0.07.
Five-year overall survival was 93% (95% CI 74–98%) in those
with a pCR and 82% (95% CI 52–94%) in those with residual DCIS
(P¼0.3) (Figure 2). For the remaining 385 patients with residual
invasive carcinoma, the 5-year overall survival was 75% (95% CI
70–79%). A significant difference in overall survival was observed
between those with a pCR (i.e. residual DCIS and no invasive or
in situ disease) and those with residual invasive carcinoma, P¼0.04.
At the time of analysis, three patients in the pCR group had died,
five in the residual DCIS group and 112 in the residual invasive
carcinoma group.
The 5-year local recurrence free survival for those with pCR
was 86% (95% CI 66–94%), which compared with 74% (95% CI
44–89%) in the residual DCIS group (P¼0.5). In the residual
invasive carcinoma group, the 5-year local recurrence free survival
was 90% (95% CI 75–90%).
In 30 patients with pCR, there were 3 (10%) local recurrences
and one (3%) contralateral nodal recurrence (axilla and suprac-
lavicular fossa). Of these 30 patients, one also developed metastatic
bone disease (3%). One woman (3%) developed high-grade DCIS
in the ipsilateral breast.
In the group of 20 women with residual DCIS, there were
4 (20%) local recurrences and a further patient who developed
a local recurrence simultaneously with pulmonary and pleural
metastatic disease. One patient each recurred with brain and bone
metastases.
Of the 385 patients with residual invasive carcinoma 32 (8%)
had isolated local recurrences and a further 24 (6%) had
concurrent local and distant recurrence.
DISCUSSION
Few patients have no residual invasive and in situ disease or
residual DCIS only following neoadjuvant chemotherapy for breast
cancer. In our series, 30 (7%) achieved a pCR and 20 (5%) residual
DCIS only. Of the patients with no residual disease, there were 3
(10%) local recurrences, 1 (3%) contralateral nodal recurrence and
one patient developed-high grade DCIS in the ipsilateral breast.
One patient in this group developed metastatic bone disease. In the
residual DCIS group, there were 4 (20%) local recurrences and a
further patient developing simultaneous local recurrence and
metastatic disease. This compares with 32 (83%) isolated local
recurrences and 24 (6%) concurrent local and distant recurrences
in the residual invasive carcinoma group. With small numbers of
patients and few events in each group this study is under powered
to detect anything but a large difference in survival between the
Table 2 Chemotherapy regimens administered to pathological complete
response and residual DCIS groups
Chemotherapy Number DCIS group Number pCR group
ECisF 6 8
AC 10 17
NE 2 3
FEC 1 1
NM 0 1
CMF–AC 1 0
ECisF: Epirubicin 60mgm
 2, day 1 of 3 week cycle; Cisplatin 60mgm
 2,d a y1o f3
week cycle; 5 Fluorouracil 200mgm
 2, 24h continuous infusion for 21 weeks. AC:
Doxorubicin 60mgm
 2, day 1 of 3 week cycle; Cyclophosphamide 600mgm
 2, day
1 of 3 week cycle. NE: Navelbine 25mgm
 2, day 1+8 of 3 week cycle (maximum
dose 60mg); Epirubicin 60mgm
 2, day 1 of 3 week cycle. FEC: 5 Fluorouracil
600mgm
 2, day 1 of 3 week cycle; Epirubicin 60mgm
 2, day 1 of 3 week cycle;
Cyclophosphamide 600mgm
 2, day 1 of 3 week cycle. NM: Navelbine 25mgm
 2,
day 1+8 of 3 week cycle; Mitoxantrone 12mgm
 2, day 1 of 3 week cycle. CMF:
Cyclophosphamide 100mgm
 2, once daily orally days 1–14; Methotrexate
40mgm
 2, day 1+8 of 4 week cycle; 5 Fluorouracil 600mgm
 2, day 1+8 of 4
week cycle.
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Figure 1 Disease-free survival in pathological complete response,
residual DCIS and residual invasive carcinoma groups. There is no
significant survival difference between pCRþDCIS vs residual invasive
carcinoma group: P¼0.07.
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sresidual DCIS and pCR group. As a consequence, it is not possible
to make definitive conclusions regarding the lack of difference
in disease-free and overall survival between these two groups
observed in this study. In addition, the very wide confidence
intervals for both disease-free and overall survival in the two
groups should be noted. Of the 268 patients treated with breast
conserving surgery, 18 (7%) had radial margins involved by
invasive carcinoma and 11 (4%) were recorded as having close
surgical margins. These numbers compare favourably with another
single institution series of 340 patients treated with neoadjuvant
chemotherapy followed by breast conserving surgery (Chen et al,
2004).
There have been a number of proposed methods for assess-
ing pathological response to neoadjuvant chemotherapy in the
treatment of early and locally advanced breast cancer.
The Chevallier classification grades residual DCIS as a lesser
response (class II) compared to complete disappearance of all
tumour on microscopic analysis (class I) (Chevallier et al, 1993).
Class III consists of invasive carcinomas with changes related to
therapy and class IV have few or no changes following treatment.
Chevallier and co-workers subsequently reported on 50 patients
treated with an anthracycline-based neoadjuvant regimen (Chollet
et al, 1997). In total, 11 (22%) cases were reported in class I and a
further four (8%) in class II. Of these patients, 12 were in class III
and 23 in class IV. However, overall and 5-year disease-free
survival between those with residual in situ carcinoma and those
with no residual invasive or in situ disease was not compared.
Recently, this group has investigated pCR in both breast
and axillary lymph nodes following neoadjuvant chemotherapy
(Chollet et al, 2002). Retrospectively, they analysed 451 patients, of
whom only 171 did not have clinically involved lymphadenopathy.
In total, 10 (13.2%) women had a class I response and 5 (6.6%)
were reported as class II. There were 41 (53.9%) and 20 (26.3)
patients in class 3 and 4, respectively. Patients in classes I and II
according to the Chevallier system had an improved 15-year
disease-free survival compared with those in classes III and IV
(P¼0.0053). However, when class I was considered alone against
the other classes, there was still a significant difference in disease-
free survival. Overall survival was not significantly different
between those with residual invasive disease and those in Chevalier
class IþII. However, a significant difference in overall survival
(P¼0.047) between class I tumours and those with residual disease
was observed.
Other classification systems have included those with no
evidence of residual in situ or invasive carcinoma together with
those tumours that have residual in situ disease.
In the NSABP B-18 trial, histological response was divided into
two groups, those with a pCR (including residual in situ disease)
and those with residual invasive carcinoma (Fisher et al, 1997).
This trial and the accompanying classification system are
important due to the number of patients recruited; 1523 women
were randomised between preoperative or postoperative AC
(doxorubicin and cyclophosphamide) chemotherapy. There was
no difference in disease-free survival or distant disease-free
survival between the two groups, but more patients who received
neoadjuvant chemotherapy compared to those given adjuvant
therapy underwent lumpectomy and radiotherapy (67.8 vs 59.8%
respectively). Relapse-free survival was significantly better in those
who achieved a pCR with neoadjuvant treatment compared to
those with residual invasive carcinoma.
Another publication with a large number of patients treated
in two prospective randomised trials utilised the classification
system proposed by Kuerer et al (1999). This has three grades;
no evidence of residual disease, o1cm
3 of macroscopic residual
tumour (residual microscopic foci of cancer cells included) and
41cm
3 of residual macroscopic tumour (Kuerer et al, 1998).
These investigators analysed 372 patients with locally advanced
breast cancer treated with four cycles of neoadjuvant chemo-
therapy in two prospective randomised studies (Kuerer et al,
1999). Of these patients, 43 (12%) had no histological evidence of
residual invasive carcinoma in both breast and axillary nodes. The
patients included in the pCR group had a significantly better
5-year overall and disease-free survival than in those with less than
pathologic complete response.
Recently, Miller and Payne have developed a novel 5 grade
system based on the degree of tumour cell loss secondary to
neoadjuvant chemotherapy (Ogston et al, 2003). Grade 5 in this
classification is defined by the presence of no malignant cells, only
vascular fibroelastic stroma, but the presence of DCIS is permitted.
A loss of more than 90% of tumour cells is classified as grade 4. An
estimated reduction between 30 and 90% of tumour cells is graded
as 3 and those with up to 30% loss of tumour cells as grade 2.
No change or some alteration to individual malignant cells but
reduction in cellularity is classified as grade 1. A consecutive series
of 176 patients with large and locally advanced breast cancers were
studied. In total, 170 of these cases were available for analysis. In
total, 26 patients (15%) were included in grade 1, 41 (24%) had
a grade 2 response and 46 (27%) were classified as grade 3. A total
of 34 women (20%) had a grade 4 response and 23 (14%) were
classified as grade 5. There was a statistically significant difference
in terms of disease-free and overall survival between those classi-
fied as grade 5 with all other patients. On multivariate analysis,
increasing pathological grade of response, negative oestrogen
receptor status and absence of histologically detectable residual
disease in axillary nodes following chemotherapy were indepen-
dent predictors of improved overall survival in this group of
patients.
A further system by Honkoop describes two grades – gross
residual or minimal residual disease, the latter including no
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Figure 2 Overall survival in pathological complete response, residual
DCIS and residual carcinoma groups. There is a significant survival
difference between a combination of pCR and residual DCIS vs the
residual invasive carcinoma group: P¼0.04.
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sresidual invasive cancer or scattered foci of cancer (Honkoop
et al, 1998). A total of 42 women treated with neoadjuvant chemo-
therapy followed by mastectomy and radiotherapy were studied.
On multivariate analysis, an improved disease-free and overall
survival were observed in those with a better pathological
response.
Sataloff et al (1995) proposed a system, which consists of four
pathological grades: complete response including DCIS, greater
than 50% therapeutic effect but less than total or near total, less
than 50% therapeutic effect but treatment change evident and no
effect. They performed a retrospective review of 36 patients with
locally advanced breast cancer treated with three cycles of
neoadjuvant chemotherapy. A modified radical mastectomy was
performed in all cases and adjuvant chemotherapy (consisting of
the same agents) was administered followed by chest wall
radiotherapy. On pathological examination of the surgical speci-
men a complete response, including DCIS, was observed in 14
cases (39%). Five tumours (14%) were reported as having greater
than 50% therapeutic effect but less than total. A less than 50%
therapeutic effect was seen in 12 (33%) of the 36 patients. No
pathologic response was demonstrated in 5 (14%) tumours. In this
series, axillary lymph node involvement was observed in 22 (61%)
of cases. Recurrences occurred in 20 (56%) of patients and these all
presented with distant metastases. A statistically significant
difference in survival between patients in the complete patho-
logical response and the other pathological groups was demon-
strated.
With most classification systems of grading pathological
response post neoadjuvant chemotherapy including patients with
residual DCIS in the pCR category, it is important to ascertain
whether there is a difference in prognosis between those with no
invasive or in situ disease and those with residual DCIS.
Even in the two large trials discussed, the number achieving
residual DCIS only or no invasive or in situ disease is relatively
small. In the NSABP B18 trial, 88 out 682 patients (13%) were
classified as having no residual invasive disease (Wolmark et al,
2001) and similarly in the 372 patients reported by Kuerer et al
(1999), only 43 (12%) achieved a pCR. Thus, with a relatively small
proportion of patients achieving a pCR following neoadjuvant
chemotherapy, any comparison between those with residual DCIS
and no invasive or in situ disease will inevitably involve relatively
small numbers of patients. As a consequence, our data are based
on a small number of cases, but they represent so far the only
results of which we are aware supporting the practice of including
patients with residual DCIS in the group of pathological complete
responders following neoadjuvant chemotherapy. Although we
have not been able to demonstrate a disease-free or overall survival
advantage for women with no residual invasive or in situ disease
compared to those with residual DCIS, our numbers are small with
relatively few events in each group and thus definitive conclusions
cannot be made. This study is under powered to detect anything
but a large difference in survival, and thus further analysis of large
prospective randomised trials and other databases are required to
confirm these findings.
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